IL-6 for Adult Still's: A New Option?
Some clinical benefits were seen among patients with adult-onset Still’s disease treated with tocilizumab…
View Resource
Long-Term Efficacy of Canakinumab in Systemic Juvenile Idiopathic Arthritis
Only inhibitors of IL-1 (canakinumab) and IL-6 (tocilizumab) are FDA approved for use in…
View Resource
Genetic Breakthrough in Systemic JIA
The identification of a genetic susceptibility locus for systemic juvenile idiopathic arthritis (sJIA) has…
View Resource
Kineret Approved for Still's Disease in EU
SOBI has announced that Kineret (anakinra) has been approved by the European Commission (EC)…
View Resource
IL-6 Inhibition Most Effective in Polycyclic Systemic JIA
The German Autoinflammatory Disease (AID) registry has studied the effects of the IL-6 inhibitor…
View Resource
IL-18 Binding Protein Effective in Adult-Onset Still's Disease
Gabay and colleagues have reported the results of a novel new recombinant human IL-18…
View Resource
IL-1 and IL-6 Inhibition Preferred in Systemic JIA
Since 2000, the German Biologics register (BiKeR) has prospectively enrolled children with juvenile idiopathic…
View Resource
Q Fever – The Intersection of Rheum and ID
Today in clinic, I saw a patient with longstanding seropositive, erosive rheumatoid arthritis who…
View Resource
Biologic Use in Adult-Onset Still's Disease
Adult-onset Still’s disease (AOSD) is the adult continum of systemic-onset juvenile idiopathic arthritis (SoJIA).…
View Resource
“The Big Sick” Movie Review
It’s Monday morning and my first patient is a newly diagnosed rheumatoid. This is his…
View Resource